Hindustan Foods Ltd Q1 FY2025 Concall Summary

Key Takeaways

• Record turnover, but a cautious tone: Revenue hit an all-time high, driven by a heatwave-fueled surge in ice cream and beverages, yet management refrained from reiterating its prior INR 4,000 crores top-line ambition, citing macro uncertainty.
• Profit growth lags EBITDA: EBITDA rose 47%, but PBT grew only 23% because depreciation and finance costs from the Baddi and shoe integrations could not be fully absorbed, a drag expected to ease as those assets ramp up.
• Shoe integration is the critical path: The shoe business is complex (50,000+ RMP masters, 3,000+ vendors) and integration is taking longer than expected; management now targets a Q3 ramp-up and a Q4 steady state, delaying the profit bridge.
• Baddi nears full stride: Exports have resumed to most markets and the anchor tenant has ramped to committed capacity, but Russian FDA approval is still a year out, capping near-term upside.
• What to watch next quarter: Whether the shoe business hits its Q3 integration milestone, the pace of Baddi’s new customer launches, and any confirmation that rural demand recovery is structural rather than election-driven.

Shoe Business Integration

• Complexity is the bottleneck: The acquisition spans multiple factory operations (stitching, cutting, assembling, sole fitting) and requires harmonizing 50,000+ RMP masters and 3,000+ vendors, a systems and people challenge that has slowed the ramp-up.
• Timeline has slipped: Management initially expected a faster ramp but now states Q3 is the right time to confidently say production is ramped up, with existing capacities reaching a steady state only by Q4.
• Capacity expansion on the horizon: Management hopes that by Q4, once existing investments are fully ramped, it will have allocated additional capital to expand shoe capacity, positioning for demand unlocked by BIS norms and import duties.
• Disclosure coming soon: Management is evaluating whether to disclose shoe business numbers separately and asks investors to wait another quarter or two for clarity on the segment’s shape and trajectory.
• Profit bridge delayed: The shoe business’s 4,500 employees have pushed up employee expenses, and until production ramps, the segment will continue to weigh on the correlation between EBITDA and PBT growth.

Kothari: "We, ourselves, as a management are a little confused about the — whether we should start disclosing the shoe business numbers separately or not."

Baddi Healthcare & Wellness

• Anchor tenant ramp-up complete: Other than Russia, all markets including domestic have ramped up to the anchor tenant’s committed capacity, and management is reasonably confident about meeting bottom-line guidance for that customer.
• Russian approval a year away: The Russian FDA approval process is expected to take another year, delaying a material export opportunity and keeping one leg of the Baddi growth story on hold.
• New customer gestation is long: OTC pharma site onboarding takes 8 months to a year due to regulatory requirements, stability trials, and combination trials; the company is currently working with a couple of customers on new product launches.
• Production record achieved: The plant clocked its highest-ever production in July 2024, and most regulatory approvals are now in hand, with exports resumed to the UAE, Australia, and Africa.

Seasonal Surge & Core Demand

• Heatwave drove record volumes: Ice cream and beverages posted their highest production ever since their respective facilities were set up, benefiting from an extended summer and extreme temperatures.
• Core FMCG picture is mixed: Management cannot make a generalized statement on core FMCG demand, noting that some categories have picked up while others have not, and it lacks the granular data to quantify the split.
• Rural demand verdict is pending: It is too early to say whether the consumption recovery is structural or a temporary lift from election spending and a weak base; management needs a couple more quarters to judge.

Kothari: "We really don't know, and it's too early to say whether this is a structural return of the consumption or this is just something which has been caused because of the money, of the elections as well as because of just the base effect of the previous year."

Margin Structure & Profitability

• EBITDA margin holds above 8%: The metric has stayed above 8% for five consecutive quarters, supported by deflationary tailwinds and better margins from the shoe and new businesses, though management cautions deflation is not yet a sustainable driver.
• PBT and PAT lag EBITDA: The divergence stems from two factors: Baddi and the shoe business have not performed as well as they should have, and the effective tax rate has increased, with management guiding to around 25% going forward.
• Business model insulates bottom line: Management emphasizes that 80-85% of business comes from dedicated manufacturing, where the top line is governed by inflation or deflation but the absolute bottom line remains constant irrespective of price movement.

Kothari: "What people need to understand from our business perspective is that the top line number for us is completely governed by the inflation/deflation while our bottom-line number remains constant irrespective of the price movement on our top line."

Ice Cream Relocation

• Factory moved to Nashik: The ice cream facility was relocated from Kundli, Haryana due to a statutory issue under the CWC Act, which permits processing but not manufacturing at the original site.
• Timeline and impact: Groundbreaking started last month, production is expected by March 2025, and the roughly two-month delay is not expected to materially affect FY turnover; management sees a bigger downside risk from inflation or deflation than from the delay itself.
• Nasik unit incorporation: An application will be filed with SEBI and Stock Exchanges in September, with the NCLT process expected to take another year, targeting completion by September 2025.

Private Label & Strategic Bets

• Private label remains small but strategic: The business is very small from a volume and value perspective, but it helps with business development and R&D; the customer count has increased, and work has begun with online retailers for the shoe category.
• Footwear and OTC Pharma as future headlines: Management is confident these categories will soon feature in press releases, though no specific timeline is given for when they will become material contributors.

Guidance & Commitments

Key Metrics